Spoken Alpha
Shattuck Labs, Inc.
Shattuck Labs designs monoclonal and bispecific antibodies targeting the DR3/TL1A immune pathway for inflammatory and immune-mediated diseases. The company's lead candidate, SL-325, is a DR3-blocking antibody in Phase 1 clinical trials for inflammatory bowel disease, with plans to advance to Phase 2 testing in Crohn's disease patients in late 2026.
Shattuck Labs, Inc is a Healthcare company operating in Biotechnology with a $622.3M market cap.
Most recent reported earnings: Q3 FY2026 (Nov 4, 2026).
4 earnings calls indexed on Spoken Alpha.
Behavioral analysis
Disclosures
Extracted from SEC 10-K filing, 2026-08-30.
Transcripts
Most recent calls indexed for this ticker. Open any call to drill into prepared remarks and Q&A.
History
Executives who appear on this company's earnings calls in our corpus, with role and tenure sourced from SEC filings. Click any name for the full role timeline and call appearance history. Per-executive behavioral deviation metrics are available to research subscribers.
Peers
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for STTK.
$ curl https://api.spokenalpha.com/v1/companies/STTKFAQ
Spoken Alpha indexes STTK's earnings call transcripts at https://spokenalpha.com/companies/STTK. Each call links to attributed speakers and parsed analyst Q&A. Shattuck Labs, Inc.'s own investor relations page is at https://ir.shattucklabs.com/overview/default.aspx.
Shattuck Labs, Inc. (STTK) held its most recent earnings call on 2023-11-10, covering fiscal Q3 2023.
Shattuck Labs, Inc. (STTK) operates in the Healthcare sector (Biotechnology industry).
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q3 FY2026 | 2026-11-04 | — | $-0.10 | — | — | — | — | EODHD |
| Q2 FY2026 | 2026-08-10 | $-0.12 | $-0.14 | +14.3% | $0 | — | — | EODHD |
| Q1 FY2026 | 2026-05-06 | $-0.13 | $-0.13 | 0.0% | $0 | — | — | EODHD |
| Q4 FY2025 | 2026-03-16 | $-0.12 | $-0.13 | +8.8% | $0 | — | — | EODHD |
| Q3 FY2025 | 2025-11-05 | $-0.14 | $-0.15 | +6.7% | $1.0M | — | — | EODHD |
| Q2 FY2025 | 2025-08-13 | $-0.24 | $-0.24 | 0.0% | $0 | — | — | EODHD |
| Q1 FY2025 | 2025-04-29 | $-0.27 | $-0.28 | +4.4% | $14.5M | — | — | EODHD |
| Q4 FY2024 | 2025-03-26 | $-0.37 | $-0.32 | -15.6% | $34.7M | — | — | EODHD |
| Q3 FY2024 | 2024-11-13 | $-0.33 | $-0.42 | +21.4% | $3.0M | — | — | EODHD |
| Q2 FY2024 | 2024-07-31 | $-0.42 | $-0.41 | -2.4% | $1.6M | — | — | EODHD |
| Q1 FY2024 | 2024-05-01 | $-0.37 | $-0.45 | +17.8% | $1.1M | — | — | EODHD |
| Q4 FY2023 | 2024-02-28 | $-0.41 | $-0.57 | +28.1% | $714.0K | — | — | EODHD |
| Q3 FY2023 | 2023-11-08 | $-0.65 | $-0.52 | -25.0% | $686.0K | — | — | EODHD |
| Q2 FY2023 | 2023-08-09 | $-0.50 | $-0.52 | +3.9% | $200.0K | — | — | EODHD |
| Q1 FY2023 | 2023-05-08 | $-0.49 | $-0.63 | +22.2% | $57.0K | — | — | EODHD |
| Q4 FY2022 | 2023-02-22 | $-0.60 | $-0.63 | +4.8% | $390.0K | — | — | EODHD |
| Q3 FY2022 | 2022-11-07 | $-0.58 | $-0.67 | +13.4% | $212.0K | — | — | EODHD |
| Q2 FY2022 | 2022-08-10 | $-0.65 | $-0.59 | -10.2% | $50.0K | — | — | EODHD |
| Q1 FY2022 | 2022-05-11 | $-0.58 | $-0.50 | -16.0% | $0 | — | — | EODHD |
| Q4 FY2021 | 2022-03-14 | $0.18 | $-0.43 | +100.0% | $30.1M | — | — | EODHD |
Source: EODHD. STTK reported actuals as published; sparse fields render as —.